Global export footprint The company has a proven export history to over 25 countries and has received regional export accolades, suggesting demand for veterinary technologies beyond the U.S. market and potential for channel partnerships or distributors in international regions.

Premier bacterin leadership MAXI/GUARD bovine M. bovis bacterin and intranasal Nasal Vac are recognized efficacy leaders, indicating opportunities to cross-sell complementary vaccines, expand herd-specific solutions, and partner with large clinics or feedlots seeking proven herd health programs.

Companion animal growth Broad companion animal product lines in dental care, dermatology, otology, and wound care suggest upsell paths into general veterinary practices and specialty clinics seeking zinc-based standards and innovative topical therapies.

Strategic leadership New chief operating officer appointed in 2021 and founder-led strategic mission imply potential for operational improvements, scalable manufacturing or supply chain enhancements, creating opportunities to position new product launches or contract manufacturing agreements.

Growth constraints Revenue currently under $1M with a mid-sized employee base indicates room for scalable sales initiatives, partner-led distribution, and value-based selling to larger practices or regional distributors to accelerate top-line growth.